Patent Office Affirms Four of Acorda’s Patents on MS Drug Ampyra Pending Court Ruling

The USPTO’s Patent Trial and Appeal Board validated four of Acorda’s patents on the multiple sclerosis drug Ampyra, but a federal court still has to determine whether five of the drug’s patents are valid before generic drugmakers can market versions of Ampyra.
Source: Drug Industry Daily